ArticleSchizophrenia research2013
Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.
Article in Schizophrenia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
- Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Involvement of the nuclear factor-κB transcriptional complex in prefrontal cortex immune activation in bipolar disorder.Translational psychiatry · 2021Article
- Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Endocannabinoid System Components as Potential Biomarkers in Psychiatry.Frontiers in psychiatry · 2020Review
- The Endocannabinoid System across Postnatal Development in Transmembrane DomainFrontiers in psychiatry · 2018Article
- Decreased 16:0/20:4-phosphatidylinositol level in the post-mortem prefrontal cortex of elderly patients with schizophrenia.Scientific reports · 2017Article
- Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.Schizophrenia research · 2016Article
- Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders.Psychological medicine · 2016Article
- The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.Biological psychiatry · 2016Review
- Molecular mechanisms and timing of cortical immune activation in schizophrenia.The American journal of psychiatry · 2015Article
- Chemokine receptors and cortical interneuron dysfunction in schizophrenia.Schizophrenia research · 2015Article
- Defects in fatty acid amide hydrolase 2 in a male with neurologic and psychiatric symptoms.Orphanet journal of rare diseases · 2015Article
- Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia.Schizophrenia research · 2014Article
- Cortical inhibitory neuron disturbances in schizophrenia: role of the ontogenetic transcription factor Lhx6.Schizophrenia bulletin · 2014Article
- [Clinical prognosis of schizophrenic patients with cannabis addiction. Between nihilism and hope].Der Nervenarzt · 2014Review
- Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.Biological psychiatry · 2014Article
- Lupus risk variants in the PXK locus alter B-cell receptor internalization.Frontiers in genetics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Adolescent cannabis use is associated with greater relative risk, increased symptom severity, and earlier age of onset of schizophrenia. We investigated whether this interaction may be partly attributable to disease-related disturbances in metabolism of the major cortical endocannabinoid 2-arachidonoylglycerol (2-AG). Transcript levels for the recently discovered 2-AG metabolizing enzyme, α-β-hydrolase domain 6 (ABHD6), were assessed using quantitative PCR in the prefrontal cortex of schizophrenia and healthy subjects (n=84) and antipsychotic- or tetrahydrocannabinol-exposed monkeys. ABHD6 mRNA levels were elevated in schizophrenia subjects who were younger and had a shorter illness duration but not in antipsychotic- or tetrahydrocannabinol-exposed monkeys. Higher ABHD6 mRNA levels may increase 2-AG metabolism which may influence susceptibility to cannabis in the earlier stages of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.